[lcus_masonry_article]<\/p>\n
Embodiment eleven in application 19\/540,453 is an Alzheimer’s cure discovery method. It uses the same or similar probability and synthesis data system to identify compounds that address amyloid plaque reduction, tau protein regulation, neuroinflammation reduction, and neuronal regeneration. Compounds such as C-H-O-N-Zn are evaluated for Alzheimer’s-specific mechanisms and synaptic function restoration.<\/p>\n
Alzheimer’s research has long focused on amyloid and tau; more recent work has emphasized neuroinflammation and neuronal repair. This patent embodiment does not claim a single silver bullet but a method\u2014backed by a defined data system\u2014for discovering and evaluating compounds across these mechanisms. The linkage to Alchemy (embodiment seven) means the same database that supports diabetes and Parkinson’s discovery also supports Alzheimer’s.<\/p>\n
The claims specify that the Alzheimer’s method uses a probability database to identify compounds for amyloid, tau, neuroinflammation, and neuronal mechanisms. That gives clear boundaries for what is covered and what licensees can build on. Figure 11 in the specification is a flowchart: compound, mechanisms, pipeline\u2014parallel in structure to the diabetes and Parkinson’s figures.<\/p>\n
The consolidated application (19\/540,453) was received by the USPTO on February 13, 2026, 7:14:20 PM ET, with payment receipt on file. Confirmation # 1134 and Patent Center # 74480330.<\/p>\n
Source: US Patent Application 19\/540,453, Section 8.11 and Claims; USPTO receipt.<\/em><\/p>\n [\/lcus_masonry_article]<\/p>\n <\/p>\n